Agios Pharmaceuticals Inc

Most Recent

  • uploads///dna _
    Company & Industry Overviews

    How Analysts View Agios Pharmaceuticals and Peers in March 2018

    Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

    By Kenneth Smith
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17

    In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017

    In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Jazz Pharmaceuticals Expects for Vyxeos

    If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

    By Margaret Patrick
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Celgene in August 2017

    Of the 27 analysts covering Celgene (CELG) in August 2017, 12 analysts recommended a “strong buy,” and ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Oncology Pipeline
    Company & Industry Overviews

    An Overview of Celgene’s Hematology and Oncology Pipeline

    In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%

    Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Small-Caps Are Topping the IBB Portfolio

    Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.